A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients th...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Byung Chul, Kim, Young Seok, Kim, Hun il, Kim, Se Hun, Park, Seung Sik, Seo, Yu Ri, Kim, Sang Gyune, Lee, Se Whan, Kim, Hong Soo, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://www.ncbi.nlm.nih.gov/pubmed/23091807
http://dx.doi.org/10.3350/cmh.2012.18.3.272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://www.ncbi.nlm.nih.gov/pubmed/23091807
http://dx.doi.org/10.3350/cmh.2012.18.3.272

Ejemplares similares